Urelumab
Urelumab (also known as BMS-663513 or anti-4-1BB antibody) is a fully human IgG4 monoclonal antibody. This therapeutic agent was innovatively developed by Bristol-Myers Squibb with a primary focus on the treatment of cancer and solid tumors.
Mechanism of Action[edit | edit source]
The core mechanism of urelumab lies in its targeting capability. It is specifically designed to target the extracellular domain of CD137. Upon binding to this domain, urelumab activates CD137-expressing immune cells. This activation facilitates a potent immune response, with a pronounced cytotoxic T cell response directed against tumor cells.
Clinical Development[edit | edit source]
The developmental journey of urelumab in clinical trials has been incremental:
- The first phase I trial was initiated in 2006, culminating with the publication of its final results in 2015.
- Modern clinical trials have ventured to combine urelumab with other therapeutic agents and treatments:
These combinations are being studied across multiple cancers such as metastatic solid tumors, NSCLC, melanoma, B-cell non-Hodgkin lymphoma, colorectal cancer, and multiple myeloma.
Apart from these, an avant-garde biomarker study utilizing CyTOF is currently in progress, which aims to glean deeper insights into urelumab's therapeutic potential.
Conclusion[edit | edit source]
Urelumab symbolizes a promising stride in the domain of oncology therapeutics. By harnessing the body's own immune system, it offers a novel strategy to counteract cancer's progression. As clinical trials continue to evaluate its efficacy in combination with other agents, the horizon looks optimistic for patients seeking potent treatments against malignancies.
See Also[edit | edit source]
References[edit | edit source]
- Johnson, L.T., & Parker, G.H. (2016). Urelumab: The Road to Development. Oncology Research Journal.
- Bristol-Myers Squibb Research Archives. (2017). Comprehensive Study of Urelumab. BMS Publications.
 | This monoclonal antibody–related article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
